Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Global DNA Repair Drugs Market by Drug Type (Alkylating Agents, Poly ADP Ribose Polymerase Inhibitors), Form (Capsules, Injectables, Tablets), Mechanism of Action, Application, Distribution Channel - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The DNA Repair Drugs Market grew from USD 8.58 billion in 2023 to USD 9.18 billion in 2024. It is expected to continue growing at a CAGR of 7.2%, reaching USD 13.97 billion by 2030.
The rising prevalence of cancer necessitates effective treatments, thereby enhancing the need for DNA repair drugs. However, developing DNA repair drugs can be resource-intensive and expensive, slowing the development process of drugs. Furthermore, developing more sophisticated DNA sequencing and analysis methods to identify repair deficits and customize drug therapies can pave the way for DNA repair drugs. Moreover, utilizing nanotechnology to enhance the delivery and effectiveness of DNA repair drugs has the potential to revolutionize treatment for rare diseases.
In the Americas, the United States and Canada represent rapid growth in DNA repair drugs due to infrastructure for drug development and delivery. Consumer needs in the Americas center on advanced treatment options and personalized medicine, reflecting a high awareness of genetic disorders and their impact.
In European Union countries, stringent regulations and a strong framework for protecting clinical trial data promote innovation while ensuring patient safety. Consumers in the EU prefer therapies that are both effective and provide minimal side effects catered to the development of DNA repair drugs.
The Africa and Middle East region presents a diverse picture where gulf countries such as the UAE and Saudi Arabia increasingly invest in healthcare infrastructure, including genetic research. Africa is making strides with initiatives to enhance healthcare capabilities, which could increase receptivity to advanced therapeutic options for genetic treatments. The APAC region is emerging as a developing region for DNA repair drugs due to significant investments in biotechnology and rapid advancements in genomic research, reflecting a strong governmental push towards revolutionizing global science.
Key Market Insights
Market Dynamics
- The market dynamics represent an ever-changing landscape of the DNA Repair Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Growing incidences of chronic and genetic diseases across the world
- Expanding clinical trials and research initiatives to develop DNA repair drugs
- Government initiatives to promote access to treatments for complex diseases
Market Restraints
- Formulation issues and complexities of DNA repair drugs
Market Opportunities
- Ongoing innovations to improve the efficacy and safety of DNA repair drugs
- Consumer preference for personalized and precision strategies to manage complex diseases
Market Challenges
- Limitations associated with efficacy and safety concerns
Market Segmentation Analysis
- Form: Significant adoption of injectables for quick delivery of medication
- Application: Growing application of DNA repair drug therapy in targeted drug delivery in oncology
Recent Developments
Merck KGaA and Jiangsu Hengrui Pharmaceuticals Co., Ltd. Forge Alliance to Advance Cancer Treatment Innovations
Merck KGaA has announced a collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd., focusing on the development of DNA damage response (DDR) drugs. This deal granted Merck KGaA the rights to develop, manufacture, and market Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s cancer drug candidate, HRS-1167, outside China.
Collaboration and Innovations in Cancer Treatment by F. Hoffmann-La Roche AG and KSQ Therapeutics, Inc. in DNA Repair Drugs
F. Hoffmann-La Roche AG has secured a global license to advance KSQ-4279, a small molecule drug, started in 2024. KSQ-4279 is currently undergoing phase 1 trials targeting solid tumors and functions by inhibiting ubiquitin-specific peptidase 1 (USP1), a protein in DNA repair processes.F. Hoffmann-La Roche AG's financial commitment included an undisclosed upfront payment along with potential milestone and royalty disbursements, reinforcing the mutual dedication to DNA repair drug development.
FDA Approves New Combination Therapy for Advanced Prostate Cancer Featuring Genetic Mutations
Pfizer Inc.'s FDA approval marked an advancement in treating metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. The approved therapy combined TALZENNA (talazoparib), a poly ADP-ribose polymerase (PARP) inhibitor, with XTANDI (enzalutamide), showing an approach in a patient subset with historically poor outcomes. Based on the Phase 3 TALAPRO-2 trial findings, this combination demonstrated a 55% reduction in the risk of disease progression or death in mCRPC patients specifically identified with mutations such as BRCA1/2 and others.
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the DNA Repair Drugs Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the DNA Repair Drugs Market, highlighting leading vendors and their innovative profiles. These include Artios Pharma, AstraZeneca PLC, Aurigene Discovery Technologies, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, CanBas Co., Ltd., Clovis Oncology, Corden Pharma International GmbH, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline PLC, Hanson Wade Group, Johnson & Johnson Services, Inc., Merck KgaA, Novartis AG, Pfizer Inc., and Valerio Therapeutics.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 187 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $9.18 Billion |
| Forecasted Market Value (USD) by 2030 | $13.97 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.2. Market Segmentation Analysis
5.2.1. Form: Significant adoption of injectables for quick delivery of medication
5.2.2. Application: Growing application of DNA repair drug therapy in targeted drug delivery in oncology
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. DNA Repair Drugs Market, by Drug Type
6.1. Introduction
6.2. Alkylating Agents
6.3. Poly ADP Ribose Polymerase Inhibitors
7. DNA Repair Drugs Market, by Form
7.1. Introduction
7.2. Capsules
7.3. Injectables
7.4. Tablets
8. DNA Repair Drugs Market, by Mechanism of Action
8.1. Introduction
8.2. Base Excision Repair Modulators
8.3. Double-strand Break Repair Modulators
8.4. Mismatch Repair Modulators
8.5. Single-strand Break Repair Modulators
9. DNA Repair Drugs Market, by Application
9.1. Introduction
9.2. Neurological Diseases
9.3. Oncology
10. DNA Repair Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
11. Americas DNA Repair Drugs Market
12. Asia-Pacific DNA Repair Drugs Market
13. Europe, Middle East & Africa DNA Repair Drugs Market
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Merck KGaA and Jiangsu Hengrui Pharmaceuticals Co., Ltd. Forge Alliance to Advance Cancer Treatment Innovations
14.3.2. Collaboration and Innovations in Cancer Treatment by F. Hoffmann-La Roche AG and KSQ Therapeutics, Inc. in DNA Repair Drugs
14.3.3. FDA Approves New Combination Therapy for Advanced Prostate Cancer Featuring Genetic Mutations
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
Companies Featured
- Artios Pharma
- AstraZeneca
- Aurigene Discovery Technologies
- Bio-Rad Laboratories
- Bristol-Myers Squibb
- CanBas Co.
- Clovis Oncology
- Corden Pharma International
- Eli Lilly and Company
- Genentech
- GlaxoSmithKline
- Hanson Wade Group
- Johnson & Johnson Services
- Merck
- Novartis
- Pfizer
- Valerio Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/vzfm49
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
